Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498170 | 0.86 | MRGPRX4 (0.55) | SLC7A5NR1H2NR1H3RXRA | |
| SCHEMBL12301533 | 0.85 | SLC7A5 (0.65) | SLC7A5CYP1A2CYP2C19LOXL2CYP4F2 | |
| SCHEMBL31068535 | 0.85 | SLC7A5 (0.58) | SLC7A5LOXL2CYP4F2CYP4A11 | |
| SCHEMBL29346854 | 0.85 | SLC7A5 (0.58) | SLC7A5LOXL2CYP4F2CYP4A11 | |
| SCHEMBL30873957 | 0.85 | SLC7A5 (0.61) | SLC7A5LOXL2NR1H2NR1H3CYP4F2 | |
| SCHEMBL7384982 | 0.84 | SLC7A5 (0.63) | SLC7A5LOXL2CYP4F2CYP4A11 | |
| SCHEMBL3499880 | 0.84 | SLC7A5 (0.63) | SLC7A5LOXL2CYP4F2CYP4A11 | |
| Hydrogen Peroxide SCHEMBL27146001 | 0.83 | SLC7A5 (0.60) | SLC7A5CYP1A2CYP2C19LOXL2 | |
| SCHEMBL10431445 | 0.83 | SLC7A5 (0.62) | SLC7A5LOXL2CYP4F2CYP4A11 | |
| SCHEMBL1246082 | 0.83 | SLC7A5 (0.62) | SLC7A5LOXL2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | SLC7A5 3402/4885CYP1A2 4441/4885CYP2C19 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.